评估NRF1-蛋白酶轴作为乳腺癌治疗点
Holly A Byers1, Amy N Brooks1, Janakiram R Vangala1
1Department of Pathology and Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Scientific reports
|September 22, 2023
概括
三重阴性乳腺癌 (TNBC) 对蛋白酶体抑制剂具有高度敏感性. 向转录因子NRF1提高了TNBC中蛋白酶体抑制剂的有效性,减少了瘤负担.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 蛋白酶对蛋白质降解至关重要,癌细胞严重依赖它们的活动.
- 与正常组织相比,在所有乳腺癌亚型中观察到高的蛋白酶子单元转录水平.
研究的目的:
- 调查蛋白酶体抑制剂在乳腺癌中的有用性,重点关注亚型特定的敏感性.
- 探索转录因子NRF1在三阴性乳腺癌 (TNBC) 对蛋白酶体抑制反应中的作用.
主要方法:
- 对TCGA乳腺癌数据集的系统分析.
- 用乳腺癌细胞系和患者衍生异种移植 (PDX) 的实验.
- 在TNBC模型中进行的活体异种移植研究,NRF1耗尽和卡菲尔佐米布治疗.
主要成果:
- 蛋白质酶子单元转录在所有乳腺癌亚型中都升高.
- TNBC对蛋白酶体抑制表现出最高的敏感性.
- 在用卡菲尔佐米布治疗的TNBC异种移植中,NRF1减弱显著降低了瘤负担.
结论:
- TNBC是一种对蛋白酶体抑制剂特别易受伤害的亚型.
- 向NRF1提供了一种潜在的策略,以提高TNBC中蛋白酶体抑制剂的疗效.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Nucleolus
8.9K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.9K
The Proteasome
873
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
873


